RxFunction, Inc. — SEC Form D Filing
RxFunction, Inc. filed an SEC Form D on October 14, 2026, reporting $4.01M raised in Medical Devices.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 14, 2026
- Amount reported
- $4.01M
- Round stage
- Seed
- Industry
- Medical Devices
- Website
- https://rxfunction.com/
What the company does
Securities: The underlying offering is complete and this amendment to the original Form D covers only the Common Stock issuable upon exercise of warrants sold in the underlying offerings.. Exemption: Rule 506(b). Incorporated: MINNESOTA
Problem
Patients with sensory peripheral neuropathy often experience numb feet, struggle with gait and balance, and face a high risk of falls due to lost foot sensation.
Solution
RxFunction provides Walkasins, a wearable lower limb sensory prosthetic device that delivers mechanical tactile stimuli to the leg, replacing lost foot sensation to improve balance, gait, and reduce fall risk for individuals with peripheral neuropathy.
Why now
Advances in wearable technology and sensory prosthetics, combined with an aging population and increased awareness of fall prevention in healthcare, create a demand for effective, non-invasive solutions for neurological conditions.
Verdict
Investors backed this round because the solution directly addressed a high-cost, high-frequency problem in an aging demographic with a clear, non-invasive device. This cleared because it offered a tangible, direct sensory replacement for a known deficit, not because it promised novel neuroplasticity or broad neurological restoration. The implicit bet was on market adoption driven by a simple functional improvement, rather than on groundbreaking scientific discovery. Upside was limited by the device's specific application and the regulatory and reimbursement hurdles typical for specialized medical devices, rather than a platform play.
Source: SEC EDGAR Form D filing